← back to the index
DV-001 contraception 1974

The Dalkon Shield — A Faked IUD That Killed Seventeen and Wrote Device Law

deathinfection-sepsisinfertilityseptic-abortioncontraceptionobstetrics-gynecology1970s1980s
Patients implanted
~4.5M across 80 countries (~2.5M U.S.)
Failure or harm
Real pregnancy rate 5-10% (vs marketed 1.1%); ~200,000 injury claims
In use
~3.5 yrs (Jan 1971 – Jun 1974 U.S. sales)
Status
Withdrawn

Summary

When the A.H. Robins Company pulled the Dalkon Shield from the U.S. market on June 28, 1974, the gap between what its inventor Dr. Hugh J. Davis had promised and what the device delivered was already measured in dead women: Davis had published a February 1970 study claiming a 1.1 percent pregnancy rate — comparable to the contraceptive pill and better than rival IUDs then quoting 2 to 3 percent — while concealing that he held a financial stake in the product, had followed roughly 640 patients for an average of only 5.5 months, told many of them to use backup contraception during the early cycles, and dropped non-compliant women from the count. Properly designed studies later put the real failure rate at 5 to 10 percent. By the time Robins acquired the device for $750,000 plus royalties in June 1970 and began mass-marketing it in January 1971, the wonder-IUD legend was built on a number its own inventor had manufactured.

The harm was not contraceptive failure alone. The Shield's distinguishing feature — a multifilament Supramid removal string sheathed in nylon — acted as a wick, drawing bacteria from the vagina past the cervix into the sterile uterus. Women who conceived with the device in place frequently miscarried in the second trimester via septic abortion, an infected and sometimes fatal mid-pregnancy loss; survivors of pelvic inflammatory disease were often left with scarred fallopian tubes and permanent sterility. Roughly 4.5 million units were sold across 80 countries before withdrawal, about 2.5 million of them in the United States. At least seventeen American women died, and hundreds of thousands suffered PID, ectopic pregnancy, or infertility — a casualty pattern with no precedent in modern contraception.

Robins did not recall the devices already inside women's bodies, and continued overseas distribution after halting U.S. sales. Litigation — not regulation — forced the truth into the open: discovery in cases tried before federal judges Miles W. Lord in Minnesota and later Robert R. Merhige Jr. in Virginia exposed internal memos showing the company had grounds to know of the wicking defect by 1971 and buried them. Facing a litigation tide it could not absorb, Robins filed for Chapter 11 bankruptcy in August 1985. Judge Merhige fixed its liability at $2.475 billion, funded by acquirer American Home Products into the Dalkon Shield Claimants Trust, which processed roughly 200,000 claims. The episode became the proximate political fuel for the 1976 Medical Device Amendments — the first U.S. law to require pre-market review of medical devices — making the Dalkon Shield the catastrophe that wrote the rulebook it had evaded.

Timeline

1968–1970
Davis and Lerner build the Shield
Johns Hopkins gynecologist Hugh J. Davis and electrical engineer Irwin Lerner develop the crab-shaped IUD; Lerner patents it and Davis becomes a financial stakeholder in the Dalkon Corporation that holds the commercial rights.
Feb 1970
The fabricated 1.1% study
Davis publishes data in the American Journal of Obstetrics and Gynecology claiming a 1.1% pregnancy rate after a mean 5.5-month follow-up on about 640 women, omitting his financial interest, masking failures with backup contraception, and excluding dropouts from the denominator.
Jun 1970
A.H. Robins buys in
Richmond pharmaceutical maker A.H. Robins, with no prior IUD experience, acquires manufacturing rights for $750,000 plus royalties, hires Davis as a paid consultant, and adds copper plus the multifilament wick string.
Jan 1971
Mass marketing begins
Robins launches the Shield nationally as the safest, most effective IUD; an internal quality-control concern about the wicking string is raised and a proposed heat-seal fix is rejected as cost-prohibitive.
1971–1974
Global distribution
Roughly 2.5 million units are implanted in the U.S. and about 2 million more abroad, reaching some 4.5 million women across 80 countries.
Mar 1973
First reported septic-abortion death
An Arizona woman wearing the Shield dies of a septic abortion after becoming pregnant with the device in place; the CDC begins tracking IUD-associated complications.
May–Jun 1974
FDA pressure and physician letter
Mounting reports of septic mid-trimester abortions prompt Robins to send a warning "Dear Doctor" letter to physicians; the FDA convenes on the device's safety.
Jun 28, 1974
U.S. sales suspended
Robins halts domestic sales of the Dalkon Shield but does not recall units already implanted and continues some foreign distribution.
Oct 1974
Septic-pregnancy case series published
Obstetrics & Gynecology publishes case reports of septic pregnancies; CDC analysis links the Shield to elevated spontaneous-abortion and death risk versus other IUDs.
1976
Medical Device Amendments enacted
Congress, citing the Dalkon Shield in hearings, passes the Medical Device Amendments to the Food, Drug, and Cosmetic Act — the first U.S. pre-market regulatory scheme for devices.
Aug 21, 1985
Robins files Chapter 11
Overwhelmed by 300,000-plus filed claims and punitive verdicts, A.H. Robins files for bankruptcy protection in Richmond, Virginia.
1988–1989
The $2.475 billion trust
American Home Products acquires Robins; Judge Robert R. Merhige Jr. fixes liability at $2.475 billion, funding the Dalkon Shield Claimants Trust to pay roughly 200,000 claimants.

The Number That Built a Wonder Device

The Dalkon Shield's reputation rested on a single statistic, and that statistic was an artifact. Hugh Davis's February 1970 study in the American Journal of Obstetrics and Gynecology reported a 1.1 percent pregnancy rate — a figure that, if true, would have placed the IUD in the same tier as the oral contraceptive and well ahead of competing intrauterine devices then quoting 2 to 3 percent. The study was structurally incapable of supporting that claim. It followed roughly 640 women for a mean of only 5.5 months — far too short to capture a contraceptive's true cumulative failure rate; during the early cycles many subjects were instructed to use additional spermicidal contraception, suppressing apparent failures at exactly the point when an IUD is most likely to fail; and women who discontinued were removed from the denominator rather than counted as the failures many of them were. Davis did not disclose that he co-owned the device's commercial rights through the Dalkon Corporation, nor that he had testified before Congress against the pill while quietly promoting his own alternative. A.H. Robins, a Richmond pharmaceutical house with no prior IUD experience, purchased the device in June 1970 on the strength of that fabricated number, hired its inventor as a paid consultant, and went to market in January 1971. By 1972 broader physician returns were already reporting pregnancy rates several times higher; when controlled studies were finally run, the real-world rate landed between 5 and 10 percent. The legend of the safest IUD in America was, from the first day of sale, a marketing claim the manufacturer had documented reason to doubt.

The Wick, the Septic Womb, and the Memo Nobody Sent Up

The defect that turned a contraceptive into a pathogen-delivery system was the very feature meant to make the device easy to remove. Unlike the monofilament tails of other IUDs, the Shield used a multifilament Supramid string — hundreds of fine fibers bundled inside a nylon sheath. That structure wicked: by capillary action it drew bacteria-laden vaginal fluid upward along the spaces between the filaments, breaching the cervical barrier that normally keeps the uterus sterile, and a sheath that abraded or split with time only widened the conduit. The consequence was a distinct and lethal pattern. Women who became pregnant with the Shield in place — already more common than advertised — were far likelier to suffer mid-trimester septic abortion, an infected miscarriage that could turn fatal within hours and that killed at least seventeen American women. Non-pregnant users developed pelvic inflammatory disease at elevated rates, and PID's frequent legacy was scarred fallopian tubes, ectopic pregnancy, and permanent infertility. The signal existed inside the company before the device was ever mass-marketed: a Robins quality-control supervisor flagged the wicking risk in 1971, and a proposed heat-seal fix — capping the string's cut end so it could not wick — was rejected as too costly to add to a high-volume disposable. The string was the thing that made the Shield distinctive in catalogues and the thing that made it deadly in bodies. The internal warning did not travel upward, the cheaper string stayed in production, and the memo flagging it stayed in a file where only discovery would later find it.

Discovery as the Only Regulator That Worked

No recall order forced the reckoning; the courts did. Through the late 1970s and early 1980s, plaintiffs' attorneys in cases overseen by federal judges Miles W. Lord in Minnesota and later Robert R. Merhige Jr. in Virginia pried loose internal Robins documents showing the company had known of the string-wicking hazard and the inflated efficacy claim years before withdrawal. Judge Lord became a public figure when, in 1984, he delivered a courtroom reprimand to three Robins executives that was entered into the Congressional Record, accusing them of having "monstrously" placed corporate profit above women's lives. Punitive-damage verdicts mounted as juries read the company's own memos, and the discovery files — not any agency finding — supplied the evidence. By 1985 Robins faced more than 300,000 claims and filed for Chapter 11 bankruptcy, a maneuver that consolidated every claimant into a single proceeding and capped the company's exposure. American Home Products acquired Robins, and in 1988–89 Judge Merhige set aggregate liability at $2.475 billion, financing the Dalkon Shield Claimants Trust. The trust ultimately processed on the order of 200,000 claims and paid out billions, though a majority of claimants accepted only modest settlements rather than litigate their injuries individually. The device had been withdrawn more than a decade before any of this resolved; the bodies and the discovery files, not any regulator, wrote the ending.

Contributing Factors

01
Conflicted-investigator efficacy fraud
The pivotal 1.1% pregnancy figure came from the device's own inventor-owner, using a short 5.5-month follow-up, backup-contraception masking, and dropout exclusion. An efficacy claim generated by a financially interested party with a methodologically rigged study became the foundation of every subsequent marketing assertion — the original sin from which all downstream harm flowed.
02
A design defect known internally and buried
The multifilament wicking string was identified as a bacterial-transport hazard by a Robins quality-control employee in 1971, and a heat-seal remedy was rejected on cost grounds. The lethal mechanism was understood inside the firm before mass distribution; the failure was not ignorance but suppression of an internal safety signal.
03
A pre-market regulatory vacuum for devices
Before the 1976 Medical Device Amendments, the FDA had no authority to require testing or approval of medical devices. The Shield reached millions of women without independent pre-market review precisely because the legal category that would have demanded it did not yet exist — a structural gap the manufacturer exploited.
04
Withdrawal without recall, and overseas dumping
Halting U.S. sales in June 1974 did nothing for the millions of devices already implanted, which Robins declined to recall, and the company continued foreign distribution. Treating market withdrawal as the endpoint — rather than retrieval of an in-body hazard — converted a U.S. problem into a prolonged global one across 80 countries.
05
Bankruptcy as a liability-capping endgame
When litigation exposure became unbounded, Chapter 11 served less as insolvency relief than as a tool to corral some 300,000 claimants into a single capped trust. The mass-tort bankruptcy converted open-ended jury risk into a fixed $2.475 billion number, a template later defendants would study and reuse.

Aftermath

The Dalkon Shield's most durable consequence was statutory: its congressional hearings supplied the political momentum for the Medical Device Amendments of 1976, which for the first time required the FDA to clear medical devices before sale and assigned them risk classes with proportionate scrutiny — the United States' first device-specific regulatory regime. The financial reckoning came through the Dalkon Shield Claimants Trust, capitalized at $2.475 billion by American Home Products after Judge Merhige's liability estimate, which processed roughly 200,000 claims before winding down around 2000; it ultimately returned more than its principal to claimants, yet most individual payouts remained small relative to the injuries they answered for. The reputational damage extended far beyond one product. IUD use in the United States collapsed for a generation: manufacturers withdrew nearly all intrauterine devices from the American market by the mid-1980s for fear of liability, and an entire category of safe, effective contraception was effectively unavailable to U.S. women into the 2000s, when copper and hormonal IUDs were finally rehabilitated. Internationally, the unrecalled and dumped devices left a tail of infections and infertility that field workers were still removing from women's bodies years after Richmond had moved on. Today the Dalkon Shield is the textbook byword for device fraud, signal suppression, and the use of bankruptcy to cap mass-tort liability — invoked whenever a manufacturer's own internal documents reveal it knew before it withdrew.

Lessons

  1. Treat any efficacy number produced by a party with a financial stake in the product as unverified until an independent, full-cohort study with adequate follow-up and intention-to-treat accounting reproduces it; exclude no dropouts.
  2. When an internal quality-control employee flags a safety mechanism, escalate and document the disposition in writing — a cost-based rejection of a known-hazard fix is the single most damaging artifact discovery will ever surface.
  3. Distinguish withdrawal from recall: pulling a product from sale does nothing about units already deployed in bodies or markets, so treat retrieval of the in-use hazard, not cessation of new sales, as the obligation.
  4. Assume the litigation discovery file is the real regulator; write every internal memo as though a jury will read it, because in mass-harm cases it will.
  5. Read the absence of a regulatory category as a hazard, not a permission — operating in a pre-market vacuum invites the very law your failure will trigger.

References